Jubilant IngreviaQ4 FY24

Jubilant Ingrevia Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹588.45P/E: 26.0Market Cap: ₹9.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 2
  • Specialty Chemical business expected to grow 3 to 3.5 times over next 3 years, constituting at least 60% of overall business.
  • Growth to be driven by CDMO, fine chemical business (pyridine and diketene derivatives), and Microbial Solutions.
  • CDMO segment seeing increasing inquiries, including semiconductors, with potential for rapid volume growth once product approvals occur.
  • Nutrition business volumes are steady and growing; vitamin B3 global market share increased in FY24 despite pricing pressures.
  • Company targets revenue potential of around Rs. 8,000 crores post ongoing capex investments.
  • Continued focus on customer-centricity and ramping up newly commissioned plants.
  • Anticipated top-line growth aligned with “Pinnacle 345” strategy aiming for 3x revenue and 4x EBITDA in 5 years.
  • Capex plans beyond FY25 indicate further expansion with Rs. 400-500 crores per annum to support 3x revenue growth from current baseline.

See what Jubilant Ingrevia management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The company had incurred a capital expenditure of Rs. 572 Cr in FY24 and plans to spend about Rs. 600-700 Cr in FY25 as part of the ongoing Rs. 2,000 Cr capex plan.
  • Despite high capex, the company limited borrowings and actually decreased net debt by Rs. 48 Cr during the second half of FY24 via working capital optimization.
  • Net debt as of March 31, 2024, stood at Rs. 653 Cr with a net debt to EBITDA ratio of 1.43 times.
  • There is no explicit mention of any immediate or planned new fundraising through debt or equity in the transcript.
  • The company may increase capex slightly beyond planned Rs. 600 Cr if long-term contracts with customers are signed, but no direct reference to raising new funds was made.

See what Jubilant Ingrevia management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Rs. 2,000 Crores capex plan announced over FY '22 to FY '25, with Rs. 1,400 Cr already committed and remaining Rs. 600-700 Cr to be spent mainly in FY '25.
  • FY '25 capex includes investments in Food and Cosmetic Grade Niacinamide plant, new food grade choline (CC/CBT) plant, and expansion of GMP facilities for CDMO business.
  • Future capex beyond FY '25 expected around Rs. 400-500 Cr per annum focusing on areas aligned with strategic priorities: Agrochemical expansions, diketene derivatives (Phase 3 and 4), microbial segment plants, and human nutrition premixes.
  • New multipurpose Agro Active & Intermediate plant commissioned at Bharuch. New Diketene Derivatives plant commissioned at Gajraula.
  • A GMP-compliant facility for Food & Cosmetic grade B3 is expected to be commissioned in Q3 FY '25.
  • Additional capex may be required (Rs. 1,500-2,000 Cr) for achieving 3x revenue growth beyond the original plan.
  • Capex investments are only approved with internal criteria of >20% EBITDA margin and >20% ROCE.

Track Jubilant Ingrevia — get its next earnings analysis in your feed

How does Jubilant Ingrevia rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisJubilant Ingrevia
Rev 2Mar 1

How does Jubilant Ingrevia rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →